array(40) {
  [0]=>
  string(4) "8329"
  ["article_id"]=>
  string(4) "8329"
  [1]=>
  string(103) "‘Significant’ fall in referrals to GPs since introduction of pharmacy consultation service"
  ["article_title"]=>
  string(103) "‘Significant’ fall in referrals to GPs since introduction of pharmacy consultation service"
  [2]=>
  string(152) "NHS 111 has seen a 6% drop in referrals to GP surgeries since the community pharmacist consultation service was launched in October 2019, according t"
  ["short_description"]=>
  string(152) "NHS 111 has seen a 6% drop in referrals to GP surgeries since the community pharmacist consultation service was launched in October 2019, according t"
  [3]=>
  string(237) "NHS 111 has seen a 6% drop in referrals to GP surgeries since the community pharmacist consultation service was launched in October 2019, according to Anne Joshua, head of pharmacy integration at NHS England and NHS Improvement."
  ["description"]=>
  string(237) "NHS 111 has seen a 6% drop in referrals to GP surgeries since the community pharmacist consultation service was launched in October 2019, according to Anne Joshua, head of pharmacy integration at NHS England and NHS Improvement."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(167) "https://www.pharmaceutical-journal.com/news-and-analysis/news/significant-fall-in-referrals-to-gps-since-introduction-of-pharmacy-consultation-service/20207827.article"
  ["blog_url"]=>
  string(167) "https://www.pharmaceutical-journal.com/news-and-analysis/news/significant-fall-in-referrals-to-gps-since-introduction-of-pharmacy-consultation-service/20207827.article"
  [15]=>
  string(19) "2020-03-13 23:26:00"
  ["add_date"]=>
  string(19) "2020-03-13 23:26:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:46"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:46"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8379"
  ["article_id"]=>
  string(4) "8379"
  [1]=>
  string(40) "COVID-19 appears less severe in children"
  ["article_title"]=>
  string(40) "COVID-19 appears less severe in children"
  [2]=>
  string(154) "As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there's reassuri"
  ["short_description"]=>
  string(154) "As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there's reassuri"
  [3]=>
  string(225) "As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there's reassuring evidence that children have fewer symptoms and less severe disease. "
  ["description"]=>
  string(225) "As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there's reassuring evidence that children have fewer symptoms and less severe disease. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200313112145.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200313112145.htm"
  [15]=>
  string(19) "2020-03-13 23:21:45"
  ["add_date"]=>
  string(19) "2020-03-13 23:21:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:17"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8416"
  ["article_id"]=>
  string(4) "8416"
  [1]=>
  string(76) "Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More"
  ["article_title"]=>
  string(76) "Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More"
  [2]=>
  string(150) "The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing "
  ["short_description"]=>
  string(150) "The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing "
  [3]=>
  string(356) "The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected. The World Health Organization this week declared that the COVID-19 outbreak was serious enough to classify as pandemic. The toll on public health […]"
  ["description"]=>
  string(356) "The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected. The World Health Organization this week declared that the COVID-19 outbreak was serious enough to classify as pandemic. The toll on public health […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(104) "https://xconomy.com/national/2020/03/13/bio-roundup-pandemic-declared-rubius-restarts-kymeras-cash-more/"
  ["blog_url"]=>
  string(104) "https://xconomy.com/national/2020/03/13/bio-roundup-pandemic-declared-rubius-restarts-kymeras-cash-more/"
  [15]=>
  string(19) "2020-03-13 21:33:56"
  ["add_date"]=>
  string(19) "2020-03-13 21:33:56"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8285"
  ["article_id"]=>
  string(4) "8285"
  [1]=>
  string(49) "£12m committed to preventable disease research"
  ["article_title"]=>
  string(49) "£12m committed to preventable disease research"
  [2]=>
  string(103) "Half of the public aren't even aware that conditions like type II diabetes may be preventable."
  ["short_description"]=>
  string(103) "Half of the public aren't even aware that conditions like type II diabetes may be preventable."
  [3]=>
  string(103) "Half of the public aren't even aware that conditions like type II diabetes may be preventable."
  ["description"]=>
  string(103) "Half of the public aren't even aware that conditions like type II diabetes may be preventable."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(85) "http://www.pharmatimes.com/news/12m_committed_to_preventable_disease_research_1329145"
  ["blog_url"]=>
  string(85) "http://www.pharmatimes.com/news/12m_committed_to_preventable_disease_research_1329145"
  [15]=>
  string(19) "2020-03-13 20:32:01"
  ["add_date"]=>
  string(19) "2020-03-13 20:32:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:41"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8443"
  ["article_id"]=>
  string(4) "8443"
  [1]=>
  string(70) "Advantages and challenges of biosimilars approved in Europe and the US"
  ["article_title"]=>
  string(70) "Advantages and challenges of biosimilars approved in Europe and the US"
  [2]=>
  string(150) "Each biosimilar has its own unique challenges on the market. At the 2019 Generic + Biosimilar Medicines Conference, Dr Amy Gutierrez, Chief Pharmacy O"
  ["short_description"]=>
  string(150) "Each biosimilar has its own unique challenges on the market. At the 2019 Generic + Biosimilar Medicines Conference, Dr Amy Gutierrez, Chief Pharmacy O"
  [3]=>
  string(322) "
Each biosimilar has its own unique challenges on the market. At the 2019 Generic + Biosimilar Medicines Conference, Dr Amy Gutierrez, Chief Pharmacy Officer of not-for-profit healthcare plan Kaiser Permanente outlined these factors for four blockbuster drugs: bevacizumab, filgrastim, rituximab and trastuzumab [1].
"
  ["description"]=>
  string(322) "
Each biosimilar has its own unique challenges on the market. At the 2019 Generic + Biosimilar Medicines Conference, Dr Amy Gutierrez, Chief Pharmacy Officer of not-for-profit healthcare plan Kaiser Permanente outlined these factors for four blockbuster drugs: bevacizumab, filgrastim, rituximab and trastuzumab [1].
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(105) "http://www.gabionline.net//Reports/Advantages-and-challenges-of-biosimilars-approved-in-Europe-and-the-US"
  ["blog_url"]=>
  string(105) "http://www.gabionline.net//Reports/Advantages-and-challenges-of-biosimilars-approved-in-Europe-and-the-US"
  [15]=>
  string(19) "2020-03-13 19:35:07"
  ["add_date"]=>
  string(19) "2020-03-13 19:35:07"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:37"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8444"
  ["article_id"]=>
  string(4) "8444"
  [1]=>
  string(55) "Amgen starts phase III trial for aflibercept biosimilar"
  ["article_title"]=>
  string(55) "Amgen starts phase III trial for aflibercept biosimilar"
  [2]=>
  string(129) "US-based biotech giant Amgen is initiating a phase III clinical trial for a biosimilar of Regeneron’s Eylea (aflibercept)."
  ["short_description"]=>
  string(129) "US-based biotech giant Amgen is initiating a phase III clinical trial for a biosimilar of Regeneron’s Eylea (aflibercept)."
  [3]=>
  string(136) "
US-based biotech giant Amgen is initiating a phase III clinical trial for a biosimilar of Regeneron’s Eylea (aflibercept).
"
  ["description"]=>
  string(136) "
US-based biotech giant Amgen is initiating a phase III clinical trial for a biosimilar of Regeneron’s Eylea (aflibercept).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(99) "http://www.gabionline.net//Biosimilars/News/Amgen-starts-phase-III-trial-for-aflibercept-biosimilar"
  ["blog_url"]=>
  string(99) "http://www.gabionline.net//Biosimilars/News/Amgen-starts-phase-III-trial-for-aflibercept-biosimilar"
  [15]=>
  string(19) "2020-03-13 19:28:39"
  ["add_date"]=>
  string(19) "2020-03-13 19:28:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:38"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8445"
  ["article_id"]=>
  string(4) "8445"
  [1]=>
  string(68) "Tackling the challenge of safe automatic substitution of biologicals"
  ["article_title"]=>
  string(68) "Tackling the challenge of safe automatic substitution of biologicals"
  [2]=>
  string(150) "The costs of biologicals are challenging the sustainability of pharmacotherapy. Affordable biosimilars are expected to trigger competition within the "
  ["short_description"]=>
  string(150) "The costs of biologicals are challenging the sustainability of pharmacotherapy. Affordable biosimilars are expected to trigger competition within the "
  [3]=>
  string(687) "
The costs of biologicals are challenging the sustainability of pharmacotherapy. Affordable biosimilars are expected to trigger competition within the biologicals market. Increasing real-world experience on biosimilars and clinical switching studies have led to position papers supporting the interchangeability of biosimilars with their reference products under the supervision of the prescriber [1]. However, the uptake of biosimilars has been poor in Finland, since physicians have been reluctant to prescribe biosimilars, especially in the outpatient setting. One option to stimulate the uptake of biosimilars is the automatic substitution of biologicals at the pharmacy level.
"
  ["description"]=>
  string(687) "
The costs of biologicals are challenging the sustainability of pharmacotherapy. Affordable biosimilars are expected to trigger competition within the biologicals market. Increasing real-world experience on biosimilars and clinical switching studies have led to position papers supporting the interchangeability of biosimilars with their reference products under the supervision of the prescriber [1]. However, the uptake of biosimilars has been poor in Finland, since physicians have been reluctant to prescribe biosimilars, especially in the outpatient setting. One option to stimulate the uptake of biosimilars is the automatic substitution of biologicals at the pharmacy level.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(116) "http://www.gabionline.net//Biosimilars/Research/Tackling-the-challenge-of-safe-automatic-substitution-of-biologicals"
  ["blog_url"]=>
  string(116) "http://www.gabionline.net//Biosimilars/Research/Tackling-the-challenge-of-safe-automatic-substitution-of-biologicals"
  [15]=>
  string(19) "2020-03-13 19:24:37"
  ["add_date"]=>
  string(19) "2020-03-13 19:24:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:38"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8441"
  ["article_id"]=>
  string(4) "8441"
  [1]=>
  string(51) "DePuy receives CE Mark for new dual mobility system"
  ["article_title"]=>
  string(51) "DePuy receives CE Mark for new dual mobility system"
  [2]=>
  string(150) "Johnson & Johnson has announced that DePuy Synthes, which produces cementless hip implants, has obtained the European CE Mark on its new Bi-Mentum"
  ["short_description"]=>
  string(150) "Johnson & Johnson has announced that DePuy Synthes, which produces cementless hip implants, has obtained the European CE Mark on its new Bi-Mentum"
  [3]=>
  string(226) "Johnson & Johnson has announced that DePuy Synthes, which produces cementless hip implants, has obtained the European CE Mark on its new Bi-Mentum Dual Mobility system for use in patients with a higher risk of dislocation."
  ["description"]=>
  string(226) "Johnson & Johnson has announced that DePuy Synthes, which produces cementless hip implants, has obtained the European CE Mark on its new Bi-Mentum Dual Mobility system for use in patients with a higher risk of dislocation."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(92) "https://www.medicalplasticsnews.com/news/ce-mark-for-dual-mobility-system-for-hips-by-depoy/"
  ["blog_url"]=>
  string(92) "https://www.medicalplasticsnews.com/news/ce-mark-for-dual-mobility-system-for-hips-by-depoy/"
  [15]=>
  string(19) "2020-03-13 19:24:09"
  ["add_date"]=>
  string(19) "2020-03-13 19:24:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:35"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8446"
  ["article_id"]=>
  string(4) "8446"
  [1]=>
  string(53) "New biosimilars partnerships from Alvotech and Biocon"
  ["article_title"]=>
  string(53) "New biosimilars partnerships from Alvotech and Biocon"
  [2]=>
  string(150) "Alvotech has formed an exclusive partnership with JAMP Pharma (JAMP) for the commercialization of its biosimilars in Canada, while Biocon has expanded"
  ["short_description"]=>
  string(150) "Alvotech has formed an exclusive partnership with JAMP Pharma (JAMP) for the commercialization of its biosimilars in Canada, while Biocon has expanded"
  [3]=>
  string(228) "
Alvotech has formed an exclusive partnership with JAMP Pharma (JAMP) for the commercialization of its biosimilars in Canada, while Biocon has expanded its collaboration with Equillium to include Australia and New Zealand.
"
  ["description"]=>
  string(228) "
Alvotech has formed an exclusive partnership with JAMP Pharma (JAMP) for the commercialization of its biosimilars in Canada, while Biocon has expanded its collaboration with Equillium to include Australia and New Zealand.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(92) "http://www.gabionline.net//Pharma-News/New-biosimilars-partnerships-from-Alvotech-and-Biocon"
  ["blog_url"]=>
  string(92) "http://www.gabionline.net//Pharma-News/New-biosimilars-partnerships-from-Alvotech-and-Biocon"
  [15]=>
  string(19) "2020-03-13 19:20:01"
  ["add_date"]=>
  string(19) "2020-03-13 19:20:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:38"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8447"
  ["article_id"]=>
  string(4) "8447"
  [1]=>
  string(48) "Allergan, Ironwood settle Linzess patent dispute"
  ["article_title"]=>
  string(48) "Allergan, Ironwood settle Linzess patent dispute"
  [2]=>
  string(150) "In early 2020, Allergan and Ironwood Pharmaceuticals (Ironwood) reached agreements with Mylan Pharmaceuticals (Mylan), Sandoz and Teva Pharmaceutical "
  ["short_description"]=>
  string(150) "In early 2020, Allergan and Ironwood Pharmaceuticals (Ironwood) reached agreements with Mylan Pharmaceuticals (Mylan), Sandoz and Teva Pharmaceutical "
  [3]=>
  string(255) "
In early 2020, Allergan and Ironwood Pharmaceuticals (Ironwood) reached agreements with Mylan Pharmaceuticals (Mylan), Sandoz and Teva Pharmaceutical Industries (Teva) to protect their irritable bowel syndrome (IBS) treatment Linzess (linaclotide).
"
  ["description"]=>
  string(255) "
In early 2020, Allergan and Ironwood Pharmaceuticals (Ironwood) reached agreements with Mylan Pharmaceuticals (Mylan), Sandoz and Teva Pharmaceutical Industries (Teva) to protect their irritable bowel syndrome (IBS) treatment Linzess (linaclotide).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "42"
  ["rss_id"]=>
  string(2) "42"
  [14]=>
  string(95) "http://www.gabionline.net//Policies-Legislation/Allergan-Ironwood-settle-Linzess-patent-dispute"
  ["blog_url"]=>
  string(95) "http://www.gabionline.net//Policies-Legislation/Allergan-Ironwood-settle-Linzess-patent-dispute"
  [15]=>
  string(19) "2020-03-13 19:17:36"
  ["add_date"]=>
  string(19) "2020-03-13 19:17:36"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:38"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8417"
  ["article_id"]=>
  string(4) "8417"
  [1]=>
  string(66) "Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO"
  ["article_title"]=>
  string(66) "Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO"
  [2]=>
  string(150) "Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque The"
  ["short_description"]=>
  string(150) "Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque The"
  [3]=>
  string(377) "Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque Therapeutics, named John Cox its CEO. Cox has been Torque’s chief executive since late 2019. Previously Cox was the CEO of Bioverativ (NASDAQ: BIIV), which he spun out from Biogen (NASDAQ: BIIB) in 2016 and oversaw […]"
  ["description"]=>
  string(377) "Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque Therapeutics, named John Cox its CEO. Cox has been Torque’s chief executive since late 2019. Previously Cox was the CEO of Bioverativ (NASDAQ: BIIV), which he spun out from Biogen (NASDAQ: BIIB) in 2016 and oversaw […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(104) "https://xconomy.com/boston/2020/03/13/repertoire-immune-taps-torque-top-exec-biogen-vet-john-cox-as-ceo/"
  ["blog_url"]=>
  string(104) "https://xconomy.com/boston/2020/03/13/repertoire-immune-taps-torque-top-exec-biogen-vet-john-cox-as-ceo/"
  [15]=>
  string(19) "2020-03-13 15:34:17"
  ["add_date"]=>
  string(19) "2020-03-13 15:34:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8418"
  ["article_id"]=>
  string(4) "8418"
  [1]=>
  string(58) "CureVac Founder Ingmar Hoerr to Replace CEO Dan Menichella"
  ["article_title"]=>
  string(58) "CureVac Founder Ingmar Hoerr to Replace CEO Dan Menichella"
  [2]=>
  string(150) "German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella"
  ["short_description"]=>
  string(150) "German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella"
  [3]=>
  string(352) "German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella joined the company in 2017 to run its US operations, which are in Boston. He took over the CEO role from Hoerr in 2018. In its statement announcing the transition, CureVac credited Menichella […]"
  ["description"]=>
  string(352) "German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella joined the company in 2017 to run its US operations, which are in Boston. He took over the CEO role from Hoerr in 2018. In its statement announcing the transition, CureVac credited Menichella […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(97) "https://xconomy.com/europe/2020/03/13/curevac-founder-ingmar-hoerr-to-replace-ceo-dan-menichella/"
  ["blog_url"]=>
  string(97) "https://xconomy.com/europe/2020/03/13/curevac-founder-ingmar-hoerr-to-replace-ceo-dan-menichella/"
  [15]=>
  string(19) "2020-03-13 15:06:39"
  ["add_date"]=>
  string(19) "2020-03-13 15:06:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}